IFNAR2 and COVID-19: In contrast, IFNAR2 was protective for only individuals who tested positive for SARS-CoV-2 against hospitalized COVID-19 (OR = 0.86, 95% CI 0.80–0.94; adjusted p = 0.03) with insufficient evidence to suggest protection for BQC19 SARS-CoV-2-negative individuals (adjusted p = 8.1 × 10–3) where it failed MR Egger intercept sensitivity testing (p = 0.02) while colocalizing (Fig. 2).